Short communication : UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazil
dc.contributor.author | Cason, Lisiane Turatti | pt_BR |
dc.contributor.author | Sprinz, Eduardo | pt_BR |
dc.contributor.author | Lazzaretti, Rosmeri Kuhmmer | pt_BR |
dc.contributor.author | Kuhmmer, Regina | pt_BR |
dc.contributor.author | Agnes, Grasiela | pt_BR |
dc.contributor.author | Silveira, Jussara Maria | pt_BR |
dc.contributor.author | Basso, Rossana Patricia | pt_BR |
dc.contributor.author | Pinheiro, Cezar Arthur Tavares | pt_BR |
dc.contributor.author | Silveira, Mariângela Freitas da | pt_BR |
dc.contributor.author | Almeida, Silvana de | pt_BR |
dc.contributor.author | Ribeiro, Jorge Pinto | pt_BR |
dc.contributor.author | Mattevi, Vanessa Sune | pt_BR |
dc.date.accessioned | 2015-03-04T01:57:52Z | pt_BR |
dc.date.issued | 2012 | pt_BR |
dc.identifier.issn | 0889-2229 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/111605 | pt_BR |
dc.description.abstract | Highly active antiretroviral therapy (HAART) has increased the survival of HIV-infected patients. However, adverse effects play a major role in adherence to HAART. Some protease inhibitors (mainly atazanavir and indinavir) act as inhibitors of uridine diphosphate-glucuronosyltransferase (UGT1A1), the enzyme responsible for hepatic conjugation of bilirubin. Variations in the promoter region of the UGT1A1 gene (UGT1A1*28, rs8175347) can influence bilirubin plasma levels, modulating the susceptibility to hyperbilirubinemia. Aiming to analyze the association between UGT1A1*28 allele and hyperbilirubinemia in individuals exposed to HAART, we evaluated 375 HIV-positive individuals on antiretroviral therapy. Individuals carrying the UGT1A1*28 allele had a higher risk of developing severe hyperbilirubinemia [prevalence ratio (PR) = 2.43, 95% confidence interval (CI) 1.08–5.45, p = 0.032] as well as atazanavir users (PR = 7.72, 95% CI = 3.14–18.98, p < 0.001). This is the first description of such an association in Brazilian HIV patients, which shows that in African-American and Euroamerican HAART users, the UGT1A1*28 allele also predisposes to severe hyperbilirubinemia, especially in those exposed to atazanavir. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | AIDS research and human retroviruses. New York. Vol. 28, no. 9 (Sept. 2012), p. 1015-1018 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Hiperbilirrubinemia | pt_BR |
dc.subject | HIV | pt_BR |
dc.subject | Terapia antirretroviral de alta atividade | pt_BR |
dc.subject | Alelos | pt_BR |
dc.title | Short communication : UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazil | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000865254 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (39951)Ciências da Saúde (10685)